$ARWR News

Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap?

ARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline - Slideshow

Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial

Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know

Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results

Arrowhead jumps as breakthrough Alzheimer’s drug clears brain barrier

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Arrowhead Reports First Clinical Validation Of TRiM Platform As ARO-MAPT Achieves Up To 73% Mean and 85% Maximum Tau Reduction

Arrowhead Announces Interim Results From Ongoing Phase 1/2a Study Of ARO-MAPT, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Alzheimer’s Disease And Other Tauopathies

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near

Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress